# Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD

Mario Cazzola [a, *], Kai M. Beeh [b], David Price [c], Nicolas Roche [d]

[a] Unit of Respiratory Clinical Pharmacology, Department of Systems Medicine, and Postgraduate School of Respiratory Medicine, University of Rome 'Tor Vergata', Via Montpellier 1, 00133, Rome, Italy
[b] Insaf Respiratory Research Institute, Biebricher Allee 34, D-65187 Wiesbaden, Germany
[c] Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Aberdeen AB25 2ZD, UK
[d] Service de Pneumologie AP-HP, University Paris Descartes (EA2511), Groupe Hospitalier Cochin, HIA du Val de Grâce 4e C, 74 Bd de Port Royal, F-75005 Paris, France

## ARTICLE INFO

## ABSTRACT

The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary disease (COPD) vary in their pharmacological class ($\beta_2$-adrenergic agonist or antimuscarinic/anticholinergic, alone or combined), durations of action and speed of onset of bronchodilator effect. In the early stages of development of a maintenance bronchodilator, the goals are to identify a molecule with the theoretically 'ideal' profile of fast onset and prolonged duration of action in comparison with existing agents, while minimizing non-specific activity at organs outside the lungs. The move towards increasing duration of bronchodilator action is generally paralleled by improved effects on clinical outcomes, and the advent of more potent agents seems likely to provide an opportunity to reduce overreliance on the use of inhaled corticosteroids in treating COPD. In terms of onset of action, an immediately perceived benefit in reducing dyspnea, although not definitively demonstrated, might prove useful in increasing adherence, which is very poor among patients with COPD. Once-daily administration may also be helpful in this respect. Shared decision-making between patient and physician in the choice of treatment is important in optimizing adherence and, thus, treatment effectiveness.

© 2015 Published by Elsevier Ltd.

## 1. Introduction

Pharmacological treatment of chronic obstructive pulmonary disease (COPD) is used to improve lung function, thereby alleviating symptoms, reducing exacerbations and improving health status and exercise tolerance [1]. These aims hold true for each of the main treatment options available, namely long-acting bronchodilators (long-acting $\beta_2$-adrenergic agonists [LABA] and long-acting muscarinic antagonists [LAMA]), inhaled corticosteroids (ICS; used only in combination with $\beta_2$-adrenergic agonists for COPD) and the various combinations of these agents. In the treatment of COPD, inhaled long-acting bronchodilators provide effective treatment against the outcomes listed above, including exacerbations and exercise tolerance, through mechanisms of increased airway patency and reduced hyperinflation [2,3]. While no treatment has been proven conclusively to reduce the accelerated decline in lung function that characterizes COPD, post-hoc analyses have reported a slower loss of lung function during treatment with long-acting bronchodilators and ICS/LABA combinations, compared with placebo, in patients with moderate-to-severe COPD [4,5].

Characteristics of an ideal new bronchodilator should include longer duration of action, with at least a 24-h sustained bronchodilator effect allowing once-daily dosing, a fast onset of bronchodilator action at least similar to that of salbutamol (thus minimizing undue reliance on rescue medication), and a favorable safety and tolerability profile [6]. An increasing number of long-acting bronchodilators have become available in recent years. Their efficacy has generally advanced in line with increasing duration of action (short-to long-acting [7]; twice-to once-daily [8,9]) and potency of bronchodilation (mono-to combination therapy [10]), without any added safety concerns [7–9,11].

Given the current or imminent availability of several long-acting bronchodilators for use in patients with COPD, is it important or

* Corresponding author. Tel.: +39 348 6412311.
E-mail addresses: mario.cazzola@uniroma2.it (M. Cazzola), k.beeh@insaf-wi.de (K.M. Beeh), dprice@rirl.org (D. Price), nicolas.roche@cch.aphp.fr (N. Roche).

necessary to distinguish between them? In this article, we compare the onset and duration of action of long-acting bronchodilators for COPD and consider whether the theoretical 'ideal' profile translates into practical and clinical advantages for patients. Data on onset and duration were obtained from a search of the literature on PubMed for the currently used long-acting bronchodilators in COPD (in English; no date restrictions), with preference given to data from phase III studies using approved doses.

## 2. Comparative pharmacological characteristics of currently available long-acting bronchodilators

### 2.1. Long-acting $\beta_2$-adrenergic agonists (LABAs)

$\beta_2$-adrenergic receptors are present in high concentrations in the smooth muscle of the lungs, predominantly the small airways. They are coupled to an intracellular G-protein ($G_s$), which is stimulated when the agonist interacts with the $\beta_2$-adrenoceptor. This sets off an intracellular signaling reaction with production of adenylyl cyclase increasing cyclic adenosine monophosphate (cAMP), leading to a fall in intracellular calcium levels, and the opening of large-conductance potassium channels. This causes hyperpolarization and relaxation of airway smooth muscle [12]. However, it has become increasingly clear that signaling through adenylyl cyclase-coupled pathways is considerably more complex and sophisticated than was considered previously, and there is still little known regarding these pathways in airway cells [13].

Several factors determine onset of effect of LABAs after delivery by inhalation. One is the time taken to reach effective concentrations at the local receptor site, with diffusion rates determined by physico-chemical properties of the drug molecule. The more lipophilic the molecule, the slower the onset; a degree of water solubility, allowing rapid diffusion into intracellular spaces, is needed for a faster onset [14,15]. High intrinsic efficacy (full agonism) at the receptor promotes a fast rate of cAMP accumulation, and this may explain the fast onset of action of some relatively lipophilic $\beta_2$-adrenoceptor agonists [16,17]. Some pharmacological properties of the various agents are summarized in Table 1 [18]. Formoterol and indacaterol have similar, high intrinsic efficacy at the $\beta_2$-adrenoceptor: 95% and 86%, respectively, relative to isoprenaline (100%). Vilanterol is somewhat lower at 70%, but still higher than salmeterol (41%) [18]. Olodaterol is reported to have 88% intrinsic efficacy at the $\beta_2$-adrenoceptor and a potency ($pEC_{50} = 9.93$) similar to that of salmeterol (9.90) and formoterol (9.73) [19]. Potency in electrical field stimulated human bronchial rings ($pEC_{50} = 9.49$) was similar to that of formoterol (9.73) [19]. Preclinical studies with olodaterol report that its onset of action is comparable to formoterol, with maximal bronchoprotection after inhalation of a single dose of olodaterol or formoterol reached within 3–6 min in guinea pigs and 10 min in dogs [19].

**Table 1**
In-vitro characterization of $\beta_2$-adrenergic agonists: potency, onset and intrinsic efficacy data [18].

| $\beta_2$-adrenergic agonist | EFS guinea pig trachea model | | cAMP detection assays ($\beta_2$-adrenoceptor) | |
| --- | --- | --- | --- | --- |
| | Potency ($pEC_{50}$) | Onset $t_{1/2}$ (min) | Potency ($pEC_{50}$) | Intrinsic efficacy ($\beta_2$)[a] |
| Vilanterol | 8.62 ± 0.27 | 5.8 ± 0.5 | 10.37 ± 0.05 | 0.70 ± 0.03 |
| Salmeterol | 6.84 ± 0.03 | 15.2 ± 0.6 | 9.80 ± 0.10 | 0.41 ± 0.01 |
| Formoterol | 8.56 ± 0.18 | 4.0 ± 0.1 | 10.14 ± 0.08 | 0.95 ± 0.04 |
| Indacaterol | 6.84 ± 0.16 | 4.0 ± 0.2 | 9.48 ± 0.08 | 0.86 ± 0.02 |

[a] Relative to isoprenaline (=1). cAMP, cyclic adenosine monophosphate; EFS, electrical field stimulated; $pEC_{50}$, negative logarithm of the half-maximal effective concentration; $t_{1/2}$, half-life; ND, not determined. Data from Ref. [18].

The relevance of low intrinsic efficacy (partial agonist activity) is unclear, particularly for COPD. All the $\beta_2$-adrenergic agonists have some (unwanted) activity at the $\beta_1$-adrenoceptor. It has been claimed that partial agonist activity at the $\beta_1$-adrenoreceptor may result in fewer cardiovascular side effects [19], but many other factors such as binding kinetics are likely to be involved. If receptor numbers are low or receptors are not working efficiently, a partial agonist will have a lower maximal effect than a full agonist and may even act as an antagonist in the presence of a full agonist. Partial agonist properties do not affect bronchodilator efficacy, but might reduce the ability of that agent or a rescue bronchodilator to reverse acute severe bronchospasm [14,20,21]. Whether the degree of intrinsic efficacy relates to tolerance or desensitization to $\beta_2$-mediated effects in long-term clinical use is unknown; again, other factors will be important, such as receptor reserve and transduction efficiency in airway smooth muscle cells [22–24].

It is unclear why LABAs are able to cause such long bronchodilation, and several contrasting hypotheses have been formulated [12]. First, the anchored binding (or exosite) hypothesis suggests that a long lipophilic tail (e.g. of salmeterol) may bind to a region of the $\beta_2$-adrenoceptor that is apart from the active receptor site, anchoring the drug to or near the receptor and allowing repeated receptor activation [25]. Second, a molecule with a degree of lipophilicity will provide a depot of drug at the receptor site by partitioning into lipid regions and cell membranes [26]. An extension to this 'diffusion microkinetics' model describes partitioning of drug into lipophilic compartments ('lipid rafts') on airway smooth muscle cell membranes, where $\beta_2$-adrenoceptors are in close contact with signaling and effector molecules, and has been proposed to account for the duration of action of indacaterol [27,28]. Third, tight binding to the $\beta_2$-adrenoceptor and formation of a ternary complex with a long dissociation half-life was proposed for olodaterol [29], but dissociation half-life alone is unlikely to account for duration of action [18].

### 2.2. Long-acting muscarinic antagonists (LAMAs)

Muscarinic antagonists are also described synonymously as antimuscarinics or anticholinergics. These agents block the effects of the endogenous cholinergic bronchoconstrictor acetylcholine, thus resulting in bronchodilation. Acetylcholine acts on a family of five G-protein-coupled muscarinic receptors (M1 to M5), of which the $M_1$ to $M_3$ subtypes are expressed in the airways [30]. $M_1$ receptors are found in parasympathetic ganglia where they facilitate neurotransmission. $M_2$ receptors occur presynaptically on airway smooth muscle and downregulate acetylcholine release while capturing released acetylcholine (autoregulation). In addition, $M_2$ receptors on airway smooth muscle couple preferentially to the G-protein isotype $G_{\alpha o/i}$, and function to counteract the $\beta_2$-adrenoceptor-mediated relaxant pathway by inhibiting the generation and accumulation of cAMP [31–33]. In the heart, $M_2$ receptors are present post-synaptically and mediate effects such as tachycardia [30]. $M_3$ receptors are expressed on airway smooth muscle, submucosal mucus glands and vascular endothelium. Pharmacological studies have indicated that under normal conditions contraction in both central and peripheral airways is mediated primarily by the $M_3$ receptor [34].

Thus, the ideal profile for a LAMA for COPD management is one in which $M_3$ receptor blockade outweighs its activity at the $M_2$ receptor in order to provide a favorable efficacy:safety ratio [12]. The LAMAs achieve this through kinetic selectivity, whereby dissociation from $M_3$ receptors is slower than from $M_2$ receptors (see Table 2). Compared with the other LAMAs listed, glycopyrronium has the most favorable ratio of $M_3$:$M_2$ receptor residency time, although whether the apparent advantage of

**Table 2**
Comparison of LAMA receptor binding: dissociation rate constants and half-lives at human $M_2$ and $M_3$ muscarinic receptors. (From Ref. [37], with data from a separate study on umeclidinium and tiotropium from Ref. [38]).

| | M2 | | M3 | | t½ $M_3/M_2$ |
|---|---|---|---|---|---|
| | $K_{off}$ ($h^{-1}$) | $t_{½}$ (h) | $K_{off}$ ($h^{-1}$) | $t_{½}$ (h) | |
| Tiotropium [37]. | $0.26 \pm 0.05$ | 2.6 | $0.026 \pm 0.005$ | 27 | 10.4 |
| Aclidinium [37]. | $0.39 \pm 0.03$ | 1.8 | $0.071 \pm 0.01$ | 10.7 | 5.9 |
| Glycopyrronium [37]. | $1.84 \pm 0.1$ | 0.37 | $0.11 \pm 0.02$ | 6.1 | 16.5 |
| | $K_{off}$ ($min^{-1}$) | $t_{½}$ (min) | $K_{off}$ ($min^{-1}$) | $t_{½}$ (min) | |
| Tiotropium [38]. | $0.023 \pm 0.008$ | $39.2 \pm 9.7$ | $0.0026 \pm 0.0003$ | $272.8 \pm 27.6$ | 7.0 |
| Umeclidinium [38]. | $0.074 \pm 0.004$ | $9.4 \pm 0.5$ | $0.0089 \pm 0.0012$ | $82.2 \pm 0.0012$ | 8.7 |

$K_{off}$, rate constant of dissociation of radiolabelled antagonist; $t_{½}$, residence half-life.

glycopyrronium vs the other agents translates into improved clinical efficacy and safety remains to be established.

Receptor kinetics may also explain differences in onset of action, in terms of time taken to achieve equilibration at the $M_3$ receptor. The predictions from simulated kinetic rate constants that tiotropium would take four to five times longer than glycopyrronium to equilibrate with the $M_3$ receptor at equi-effective concentrations were confirmed in the in-vitro calcium assay (glycopyrronium was 5-fold faster) and the rat tracheal strip assay (2.5-fold) [35].

However, slow dissociation from the $M_3$ receptor does not appear to explain fully the duration of action of the LAMAs. $M_3$ dissociation rates of glycopyrronium and tiotropium were reduced 3-fold under physiological conditions, compared with under non-physiological conditions, to a level that was incompatible with their known 24-h duration of action [35]. A process of rebinding of freshly dissociated drug was proposed with respect to these agents, perhaps through micro-anatomical constraints at a local tissue level that restrict the free diffusion of drug molecules away from the local environment where the receptors are concentrated [35,36].

### 2.3. Combination of LABA and LAMA

A synergistic (i.e. more than additive) bronchodilator effect of a LABA and LAMA has been demonstrated in airway preparations in vitro and in patients with COPD [39,40]. These preliminary studies support the scientific rationale for combining the two types of drugs but preclinical data investigating synergy are limited and further work is required. In theory, a synergistic effect may be explained by removal of the bronchoconstrictor effects of acetylcholine by the antimuscarinic, allowing an amplified $\beta_2$-adrenergic-agonist-induced bronchodilation [31], and also by interactions between the post-receptor intracellular signaling pathways for $M_3$ and $\beta_2$-adrenoreceptors, resulting in an overall amplification of effect [34,41]. This forms the mechanistic basis for treating patients with COPD with a combination of bronchodilators that have different mechanisms of action. Whether such synergism is relevant to increasing the speed of onset or prolonging the duration of bronchodilator effect is unknown.

### 3. Onset and duration of effect of long-acting bronchodilators

Onset and duration of a bronchodilator are properties that have not been defined formally in clinical terms. Onset of effect may be expressed in various ways, usually the earliest time at which a significant effect is achieved vs placebo, or the time taken to reach a particular level of bronchodilation (e.g. 100 or 200 mL, or 12% or 15% increase from baseline). Other possibilities are time to peak effect, or time to half-maximal effect. The effect is usually expressed in terms of forced expiratory volume in 1 s ($FEV_1$). Onset may also describe a statistically or clinically significant bronchodilator effect

on day 1 of treatment, which is achieved by some of the current long-acting bronchodilators. Most LABAs and LAMAs take about 1 week to achieve pharmacokinetic steady state (up to 2–3 weeks with indacaterol and tiotropium), but any difference in bronchodilator effect between first dose and steady state will also depend on other factors such as the degree of accumulation of drug during this time, and the nature of the relationship between pharmacokinetic and pharmacodynamic variables [42]. Glycopyrronium takes 1 week to achieve pharmacokinetic steady state but pharmacodynamically achieves its full bronchodilator effect after the first dose [43–45] (see Table 3).

Duration of effect and dosing interval or frequency (e.g. once or twice daily) are not necessarily the same but are closely interrelated and are a function of maintenance dose and pharmacokinetics. The development of the once-daily bronchodilators reviewed here had from the outset the aims of designing a molecule with long-acting bronchodilating properties that would prove suitable for once-daily dosing, with initial clinical studies confirming safety, tolerability and pharmacokinetics. Dose-ranging clinical studies, usually measuring lung function, were then employed to establish the minimum effective doses given once- or sometimes twice-daily [46]. Duration of effect can be dose-dependent [47]. Aclidinium was originally investigated as a once-daily drug given at doses of 200 or 400 μg but was found to be suboptimal in terms of effect size and duration; 400 μg twice daily showed greater efficacy than the 200 μg dose and this regimen was approved for use [48]. Regulatory perspectives on what constitutes a minimum effective dose may vary, resulting in the approval of different doses and regimens of a given drug at different times and in different regions; for example, indacaterol is approved at a once-daily dose of 75 μg in the USA and at doses of 150 and 300 μg in other countries. On the other hand, the older drug formoterol, introduced in 1990, was approved for use twice daily, yet its bronchodilator effect may last for only 6 or 8 h post-dose [49].

In clinical drug trials in COPD, duration of bronchodilator effect may be the length of time post-dose during which a statistically significant and/or clinically important bronchodilator effect on $FEV_1$ in relation to placebo is maintained, either in absolute terms or as relative change from baseline. A 100 mL difference in pre-dose or trough $FEV_1$ has been reported as the minimum clinically important difference that is perceptible to patients [50]. Bronchoprotection is often used as a measure of duration of effect in asthma, but has no corollary in COPD.

Both onset and duration are typically assessed in terms of changes over time in $FEV_1$, which is widely used, easy to measure, and a required variable in regulatory clinical drug trials. In the specialized setting, a more comprehensive assessment of bronchodilator effects can be obtained using sensitive methods such as oscillometry and body plethysmography [51]. $FEV_1$ may be insensitive to some important physiological abnormalities in COPD, such as hyperinflation [52]. However, the relevant measures of lung volume require

**Table 3**
Onset of bronchodilator effect.

| | | FEV$_1$ difference vs placebo at 5 min post-dose (mL)[a] | Other onset variable (time is post-dose)[a] | Ref. |
|---|---|---|---|---|
| SABAs | Salbutamol 200 µg | 90 (95% CI 60, 120) | 7.9% (95% CI 5.5, 10.3) increase at 5 min vs placebo<br>36% of patients with ≥12% increase at 5 min vs baseline<br>23% of patients with ≥12% and >200 mL increase from baseline | [56] |
| Twice-daily LABAs | Formoterol 12 µg | 140 (95% CI 120, 160) | | [57] |
| | | — | 10% decrease of R$_{aw}$ at 1.4 ± 0.9 min | [58] |
| | | — | 7.2% increase in FEV$_1$ at 5 min vs predose<br>23% of patients with ≥12% increase in FEV$_1$ at 5 min | [59] |
| | Salmeterol 50 µg | 60 (95% CI 40, 80) | | [9] |
| | | — | 10% decrease of R$_{aw}$ at 15.1 ± 34.5 min | [58] |
| | | — | 4.1% increase in FEV$_1$ at 5 min vs predose<br>9% of patients with ≥12% increase in FEV$_1$ at 5 min | [59] |
| Once-daily LABAs | Indacaterol 150 µg | 100 (95% CI 70, 130) | 7.9% (95% CI 5.4, 10.3) increase at 5 min vs placebo<br>28% of patients with ≥12% increase from baseline at 5 min<br>19% of patients with ≥12% and >200 mL increase from baseline at 5 min | [56] |
| | | 120 (95% CI 100, 140) | | [60] |
| | | 110 (95% CI 90, 130) | | [9] |
| | | — | FEV$_1$ AUC$_{0-4h}$: 160 mL increase vs placebo* | [10] |
| | Indacaterol 300 µg | 120 (95% CI 90, 150) | 10.1% (95% CI 7.7, 12.5) increase at 5 min vs placebo<br>46% of patients with ≥12% increase from baseline at 5 min<br>28% of patients with ≥12% and >200 mL increase from baseline at 5 min | [56] |
| | | 130 (95% CI 110, 150) | | [57] |
| | Vilanterol 25 µg | 69 (95% CI −8, 146) | | [61] |
| | | — | Time to ≥12% increase from baseline: 18 min<br>Time to ≥100 mL increase in FEV$_1$ from baseline: 6 min | [62] |
| | | — | 131 mL increase in FEV$_1$ after 15 min vs placebo<br>Time to ≥100 mL increase in FEV$_1$ from baseline: 27 min | [63] |
| | | — | Time to ≥100 mL increase in FEV$_1$ from baseline 31 min | [64] |
| | Olodaterol 5 µg | 118* | | [65] |
| Twice-daily LAMAs | Aclidinium 400 µg | — | At 15 min: ~70 mL (est.) increase in FEV$_1$ vs placebo* | [66] |
| Once-daily LAMAs | Tiotropium 18 µg | 45*[b] | At 15 min: 78 mL increase in FEV$_1$ vs placebo*<br>FEV$_1$ AUC$_{0-4h}$: 141 mL increase vs placebo* | [67] |
| | | 60 (95% CI 30, 80)[b] | | [60] |
| | | — | sGaw 0.08 (0, 0.15) 1/kP*s vs placebo at 5 min<br>FRC −200 mL (95% CI −340, −60) vs placebo at 5 min | [68] |
| | | — | 39 mL (95% CI 6, 71) from predose at 10 min<br>≥12% rise in FEV$_1$ after 79 min (95% CI 18, 140) | [69] |
| | | — | ~120 mL at 30 min (est.) | [70] |
| | | — | FEV$_1$ AUC$_{0-4h}$: 140 mL increase vs placebo* | [10] |
| | Glycopyrronium 50 µg | 93* | At 15 min: 144 mL increase in FEV$_1$ vs placebo*<br>IC 181 mL vs placebo* at 25 min | [71] |
| | | 87* | At 15 min: 143 mL increase in FEV$_1$ vs placebo*<br>FEV$_1$ AUC$_{0-4h}$: 197 mL increase vs placebo* | [67] |
| | | — | FEV$_1$ AUC$_{0-4h}$: 190 mL increase vs placebo* | [10] |
| | Umeclidinium 62.5 µg | — | Time to increase in FEV$_1$ ≥100 mL above baseline: 56 min FEV$_1$ AUC$_{0-6h}$: ~135 mL (est.) increase vs placebo | [64] |
| LAMA/LABAs | QVA149 (indacaterol/glycopyrronium 110/50 µg) | 126* | FEV$_1$ AUC$_{0-4h}$: 210 mL increase vs placebo* | [72] |
| | | 130* | FEV$_1$ AUC$_{0-4h}$: 220 mL increase vs placebo* | [10] |
| | | — | sG$_{aw}$ 0.21 (0.14, 0.29) 1/kP*s vs placebo at 5 min<br>FRC −300 mL (95% CI −440, −160) vs placebo at 5 min | [68] |
| | Umeclidinium/vilanterol 62.5/25 µg | — | At 15 min: 112 mL increase in FEV$_1$ vs placebo<br>Time to increase in FEV$_1$ ≥100 mL from baseline: 27 min | [64] |

Values estimated from graphs are denoted by the '~' symbol and qualified as (est.). FEV$_1$ AUC$_{0-4h}$, FEV$_1$ averaged over 0–4 h post-dose; FRC, functional residual capacity; FEV$_1$ AUC$_{0-4h}$, area under the FEV$_1$ curve from 0 to 4 h; IC, inspiratory capacity; R$_{aw}$, airway resistance; sG$_{aw}$, specific airway resistance.

[a] Statistical significance denoted by *p < 0.05 or 95% confidence intervals.
[b] Open label.

relatively sophisticated equipment, and inspiratory capacity is often used as a surrogate measure of hyperinflation [3]. Measurements of airway resistance have been shown to correlate better than FEV$_1$ with acute bronchodilator-induced changes in dynamic hyperinflation, gas trapping, and dyspnea at rest [53]. Similarly, bronchodilator-induced improvements in exertional dyspnea have been observed in the absence of changes in FEV$_1$ [54,55].

Tables 3 and 4 compare the onset and duration of bronchodilator effect reported in clinical studies with the various long-acting agents. Salbutamol is included in Table 3 as an example of a fast-onset 'rescue' bronchodilator.

Among the LABAs, formoterol, indacaterol and olodaterol appear to share a fast onset of bronchodilator effect (Table 3). Although the available literature does not fully characterize all the

**Table 4**
Trough $FEV_1$ (difference vs placebo in mL [95% CI] unless otherwise stated) at 24 h post-dose[a] after first day's dosing, after 12 weeks and at last study day in clinical trials of long-acting bronchodilators.

| | | Day 1 | Week 12 | Last time point of study | Ref. |
|---|---|---|---|---|---|
| Twice-daily LABAs | Formoterol 12 µg | 110 (90, 130) | 70 (40, 100) | 50 (10, 90) (wk 52) | [57] |
| | Salmeterol 50 µg | 120 | 110 | 110 mL (wk 26) | [9] |
| | | − | 7.6% from baseline | 6.2% from baseline | [73] |
| Twice-daily LAMAs | Aclidinium 400 µg | Not reported | 105 change from baseline vs placebo | 128 ± 22 change from baseline vs placebo (wk 24) | [74] |
| Once-daily LABAs | Indacaterol 150 µg | 130 | 170 | 180 (wk 26) | [9] |
| | | 110 (80, 130) | 180 (140, 220) | 160 (120, 190) (wk 26) | [60] |
| | | 110 (90, 140) | 150 (120, 180) | 130 (100, 160) (wk 26) | [10] |
| | Indacaterol 300 µg | 140 (110, 160) | 170 (130, 200) | 160 (120, 200) (wk 52) | [57] |
| | Vilanterol 25 µg | Not reported | Not reported | −30 from randomization[b] (wk 52) | [75] |
| | | ~90 (est.) | ~90 (est.) | 72 (32, 112) (wk 24) | [64] |
| | | ~105 (est.) | ~100 (est.) | 114 (wk 24) | [63] |
| | | ~105 change from baseline (est.) | ~100 change from baseline (est.) | 121 change from baseline (wk 24) | [76] |
| | Olodaterol 5 µg | Not reported | 91 | 92 (wk 48) | [65] |
| | | Not reported | 47 | 68 (wk 48) | [65] |
| | | Not reported | 83 | 68 (wk 48) | [77] |
| | | Not reported | 59 | 44 (wk 48) | [77] |
| Once-daily LAMAs | Tiotropium 18 µg | 100 (70, 120)[c] | 140 (100, 180)[c] | 140 (100, 180)[c] (wk 26) | [60] |
| | | 83[c] | 83[c] | 89[c] (wk 52) | [67] |
| | | 120 (90, 140)[c] | 130 (100, 170)[c] | 130 (90, 160)[c] (wk 26) | [10] |
| | | Not reported | Not reported | 120−150 (over 1 year) | [70] |
| | | Not reported | Not reported | 137 (wk 24) | [8] |
| | Glycopyrronium 50 µg | 105 | 108 | 113 (wk 26) | [71] |
| | | 91 | 97 (65, 130) | 108 (wk 52) | [67] |
| | | 110 | 120 | 120 (80, 150) (wk 26) | [10] |
| | Umeclidinium 62.5 µg | ~105 (est.) | ~135 (est.) | 115 (76,155) (wk 24) | [64] |
| LABA/LAMAs | QVA149 (indacaterol/glycopyrronium 110/50 µg) | 190 (170, 210) | 230 (190, 260) | 200 (170, 240) L (wk 26) | [10] |
| | | Not reported | 163 | 189 (wk 52) | [78] |
| | Umeclidinium/vilanterol 62.5/25 µg | ~155 (est.) | ~190 (est.) | 167 (128, 207) (wk 24) | [64] |
| | | ~190 (est.) | ~185 (est.) | 211 (wk 24) | [76] |
| | | ~195 (est.) | ~205 (est.) | 208 (wk 24) | [76] |

Values estimated from graphs are denoted by the '~' symbol and qualified as (est.).
[a] For the twice-daily agents, 12 h following the second dose of the day.
[b] ICS withdrawn at randomization.
[c] Open label.

LAMAs, glycopyrronium (NVA237) appears to have the fastest onset of action.

As shown in Table 4, the majority of bronchodilators have an effect on trough $FEV_1$ after the first day's dosing that is very close to or exceeds the reported minimal clinically important difference of 100 mL [50], the level at which patients may perceive a benefit, although results at this time point for olodaterol are not reported. On repeated dosing over several months, both olodaterol and vilanterol appear to have modest bronchodilator effects when viewed against results from studies with other long-acting agents. Comparing effects on trough $FEV_1$ at week 12 and a later (e.g. week 26 or 52) time point, there was a loss of effect with formoterol and a suggestion of a similar phenomenon, or at least inconsistent long-term effects, with vilanterol and olodaterol. Indacaterol generally maintained its effect over 1 year (Table 4). This apparent difference between LABAs may relate to the high intrinsic efficacy of formoterol, and maybe vilanterol. The process of $\beta_2$-adrenoreceptor desensitization with prolonged exposure to $\beta_2$-adrenergic agonist varies between cells, airway smooth muscle being less prone to the phenomenon than inflammatory cells (which may explain why tachyphylaxis in asthma manifests more commonly as loss of bronchoprotection rather than loss of bronchodilation) [21,79]. Tolerance to the typical $\beta_2$-mediated adverse events of tachycardia and tremor has been reported [21,80]. The LAMAs appear to have a consistent effect over time, with glycopyrronium and tiotropium maintaining trough $FEV_1$ at levels of 100 mL or more over 1 year. Studies with the newer LAMAs, aclidinium and

umeclidinium, currently extend only up to treatment periods of 6 months. The combination LABA/LAMAs have a bronchodilator effect over time that is approximately 80−90% of the additive effect of the individual components [10,64].

Based on the data in Tables 3 and 4, indacaterol and glycopyrronium would figure prominently if a bronchodilator were to be chosen based on its rapid onset of bronchodilation, duration and magnitude of effect after a single dose, and persistence of bronchodilator effect during long-term use. However, whether their pharmacological advantages translate into superior benefits in terms of adherence, persistence or other patient perceptions remains to be demonstrated.

## 4. Benefits of fast onset of (bronchodilator) action

It might be expected that fast-onset bronchodilation would translate into fast relief of dyspnea (as in the case of salbutamol used as rescue medication). A recent study showed that changes in airway resistance (not $FEV_1$) 1 h after dosing with indacaterol 300 µg correlated with reductions in hyperinflation and gas trapping, and improvement in patient-reported dyspnea [53]. In a study comparing two fast-acting bronchodilators (formoterol and salbutamol) with the slower-acting salmeterol and oxitropium, the faster-acting agents induced a greater increase in $FEV_1$ and inspiratory capacity at 30 min post dose [81]. There was a significant correlation between acute bronchodilator effect and symptom improvement, which was strongest in patients with baseline

hyperinflation (Fig. 1). On repeated dosing, fast onset may not be particularly useful in patients who take their treatment regularly and have relatively stable symptoms. Conversely, it might be of help in patients with suboptimal adherence to treatment, since perceived rapid efficacy could reinforce compliance. It could also be useful in patients with more variable symptoms.

In some patients with COPD, symptoms vary over the day, with morning considered to be the time when symptoms are more severe [82]. It might be hypothesized that fast-acting agents could be more effective on these symptoms than those with a relatively slow onset of action, by providing rapid relief of symptoms after morning dosing [83]. In a 1-week crossover study, a twice-daily ICS/LABA containing budesonide and formoterol improved morning activities to a greater extent than twice-daily SFC [84] because of the faster onset of action of formoterol, compared with salmeterol. Similarly, in a 12-week study, the addition of the budesonide/formoterol combination to tiotropium resulted in increased $FEV_1$ immediately post-dose and an improvement in morning symptoms and activities, compared with tiotropium alone [85]. However, despite their possible association with poorer health status and more frequent

exacerbations, it is not known if morning symptoms represent some kind of phenotype in that such symptoms might be particularly pronounced in some patients independently of overall clinical severity [86]. The question remains difficult to answer in the absence of a validated, dedicated assessment tool.

An early (day 1) onset of effect may be useful in the context of a pulmonary rehabilitation program, where optimizing bronchodilator therapy at the outset has been recommended [87]. In COPD, exercise is limited by breathing discomfort (dyspnea) before leg discomfort (peripheral muscle fatigue) [88]. By overcoming dyspnea with a bronchodilator, the exercise program could focus on improving peripheral muscle function [87]. If the commencement of treatment coincides with the start of the exercise program, there may be a benefit for patients. Among the once-daily bronchodilators, in studies using submaximal constant load cycle ergometry testing, both LAMAs glycopyrronium and tiotropium were reported to increase exercise endurance time and exertional dyspnea when evaluated 2–3 h post-dose on the first day of treatment, with reduction in leg discomfort occurring at a later assessment [88,89]. The LABA indacaterol improved exercise endurance time but not exertional dyspnea (measured at end of exercise) after the first dose [90].

## 5. Benefits of sustained duration of effect

### 5.1. Once-daily vs twice-daily bronchodilators

In terms of standard clinical outcomes (lung function, symptoms and health status) measured in clinical studies, the once-daily bronchodilators (LAMA or LABA) have generally performed better than the twice-daily agents (LABAs), where comparisons have been performed [8,9,57,91,92] (Table 5). Of note, the 1-year POET study showed that, in patients with moderate-to-very-severe COPD, the once-daily LAMA tiotropium was more effective than the twice-daily LABA salmeterol in preventing exacerbations [93]. This finding cannot necessarily be extrapolated to other LABAs.

### 5.2. Comparison of once-daily bronchodilators with different onsets of action

Among the once-daily bronchodilators, tiotropium is the most commonly employed active comparator, as it was the first once-daily inhaled bronchodilator available. In several studies, bronchodilators with a fast onset have been compared with tiotropium (Table 6). As previously shown in Table 3, glycopyrronium has a faster onset of action than tiotropium. For clinical outcomes (Table 6), the two LAMAs had similar effects on symptoms, health status, rescue-medication use and exacerbations. The once-daily LABA indacaterol performed better than tiotropium for symptoms and health status [94], but tiotropium was more effective in preventing exacerbations in patients with severe or very severe airflow limitation [95] (Table 6). Indacaterol, may, therefore be more useful clinically in patients at low risk of exacerbations (the GOLD-defined patient Groups A and B), although this hypothesis requires formal testing. It should be noted that the studies summarized in the table were not necessarily designed or powered to compare the selected treatments and endpoints shown in the table.

## 6. Adherence/persistence

Adherence is poor in COPD, typically around 50% in practice [98–102]. Poor adherence is associated with worse clinical and economic outcomes [103–107]. Many factors are implicated [102], including the patient's understanding of the disease and their

**Fig. 1.** Relationship of changes in dyspnea measured by visual analogue scale with placebo correction (%) with changes in (A) $FEV_1$ and (B) IC 30 min after bronchodilation in patients with baseline IC lower than 80% predicted. (A) $r = 0.52$; $r^2 = 0.27$; $p < 0.001$; (B) $r = 0.70$; $r^2 = 0.48$; $p < 0.001$. In patients with IC >80% predicted (not shown), the correlations were $r = 0.21$; $r^2 = 0.05$; $p = 0.26$ for $FEV_1$ and $r = 0.38$; $r^2 = 0.15$; $p < 0.05$ for IC. $FEV_1$, forced expiratory volume in 1 s; IC, inspiratory capacity; pred, predicted; r, correlation coefficient; $r^2$, coefficient of determination. Reproduced with permission of the European Respiratory Society [81]. © European Respiratory Society (2003).

**Table 5**
Once-daily (qd) vs twice-daily (bid): bronchodilation, health status and symptom-based outcomes (measured at end of study unless otherwise stated) in phase III studies of ≥12 weeks' duration.

| Comparison | Bronchodilation (trough $FEV_1$) | Symptoms | Health status | Rescue use over study duration | Exacerbations (moderate/severe) as efficacy outcome | Ref. |
|---|---|---|---|---|---|---|
| Tiotropium 18 μg qd (n = 209) vs salmeterol 50 μg bid (n = 213), 24 wks | 52 mL (p < 0.01) | TDI score difference 0.78 points (p < 0.05); 42% vs 35% responders (NS) | SGRQ total score difference −1.6 units (NS); 51% vs 40% responders (p < 0.05) | Change from baseline −1.45 vs −1.44 puffs/d (NS) | NR | [8] |
| Indacaterol 150 μg qd (n = 333) vs salmeterol 50 μg bid (n = 334), 6 mo | 70 mL (p < 0.001) | TDI score 1.45 vs 0.90 (p < 0.05) (wk 12); 57−61% vs 49−54% responders[a] (wks 4−26) | −5.0 and −4.1 vs placebo; 53% and 49% responders[a] | Change from baseline −1.3 vs −1.2 puffs/d (NS) | NR | [9] |
| Indacaterol 150 μg qd (n = 560) vs salmeterol 50 μg bid (n = 563), 12 wks | 60 mL (p < 0.001) | TDI score difference 0.63 points (p < 0.001); 69.4% vs 62.7% responders (p < 0.05) | NR | Difference −0.18 puffs/d (p < 0.05) | NR | [91] |
| Indacaterol 300 μg qd (n = 437) vs formoterol 12 μg bid (n = 435), 1 yr | 110 mL (p ≤ 0.001) | TDI score difference 0.29 points (NS) | SGRQ score difference −0.7 units (NS) | Difference −0.34 puffs/d (p < 0.05) | 0.60 vs 0.56 per year (NS); 32.8 vs 31.5% of patients (NS) | [57] |
| Tiotropium 18 μg qd (n = 158) vs aclidinium 400 μg bid (n = 171), 6 wks | Difference in change from baseline −38 mL (NS) | E-RS total score −0.7 (NS) | NR | Difference −0.7% rescue-free days (NS) | NR | [66] |
| Tiotropium 18 μg qd (n = 221) vs formoterol 12 μg bid (n = 210), 6 mo | NR | Total daily symptom score 4.50 vs 4.29 (median)[a,b] | SGRQ score differences vs placebo: −2 vs −3 units | 0.67 vs 1.30 puffs/d (median)[a] | 10.4 vs 8.1% of patients (moderate) (p < 0.05, formoterol vs placebo); 2.3% vs 0.5% (severe) | [92] |
| Tiotropium 18 μg qd (n = 3707) vs salmeterol 50 μg bid (n = 3669), 1 yr | NR | NR | NR | NR | 17% reduction in risk (p < 0.001); rate ratio 0.89 (95% CI 0.83, 0.960); p = 0.002 | [93] |

Responders are those patients with an improvement from baseline equal to or exceeding the minimum clinically important difference (TDI ≥1 point; SGRQ ≥ −4 units). E-RS, EXAcerbations of Chronic pulmonary disease Tool (EXACT)-Respiratory Symptoms; NR, not reported; NS, not significantly different; SGRQ, St George's Respiratory Questionnaire; TDI, transition dyspnea index.
[a] Statistical comparison not reported.
[b] Total daily symptom score = sum of scores for breathlessness, cough, wheeze, amount and color of sputum, each scored on a 0−3 scale where 0 = no symptoms.

medication and inhaler [106,108−111], and frequency of dosing [98,102,112−114].

The relative simplicity and convenience of once-daily dosing (compared with multiple daily dosing) may encourage patients' adherence and persistence with their long-term medications. In one retrospective study of a claims database, adherence was strongly correlated with dosing frequency, with 43.3, 37.0, 30.2 and 23.0 percentage days covered for patient cohorts receiving once, twice, three times or four times daily treatment [112]. Similarly, in a study to determine the effect of dosing frequency of mometasone

**Table 6**
Selected treatment comparisons (at study endpoint) between glycopyrronium or indacaterol vs tiotropium for health status and symptom-based outcomes.

| Comparison | Symptoms (TDI total score, points) | Health status (SGRQ total score, units) | Rescue use over study duration, puffs/day | Moderate/severe exacerbations, rate ratio (95% CI) | Ref. |
|---|---|---|---|---|---|
| Glycopyrronium vs tiotropium open label, 52 wks | −0.1 (NS) | −0.5 (NS) | 0.3 (NS) | 0.82 (0.61, 1.09) (NS)[b] | [67] |
| Glycopyrronium vs tiotropium blinded, 12 wks | −0.2 (NS) | 0.7 (NS) | 0 (NS) | 1.10 (0.62, 1.93) (NS) | [96] |
| Glycopyrronium vs tiotropium, 26 wks | Differences from placebo: 0.9 vs 0.6 (NS) | Differences from placebo: −1.8 vs −0.9 (NS) | Differences from placebo: −0.3 vs −0.4 (NS) | N/A | [10] |
| Glycopyrronium vs tiotropium, 62 wks[a] | N/A | −0.6 (NS)[b] | N/A | 1.03 (0.91, 1.16) (NS)\ | [97] |
| Indacaterol 150 μg and 300 μg vs tiotropium 18 μg od (open label), 26 wks | Differences from placebo: 1.0 and 1.2 vs 0.9 (NS) | Differences from placebo: −3.3* and −2.4 vs −1.0 (*p < 0.05 vs tiotropium; NS for 300 μg) | Changes from baseline: −1.5* and −1.6* vs −1.0 (*p < 0.05 vs tiotropium; NS for 300 μg) | 0.96 (0.64,1.43) and 1.06 (0.71,1.57) (NS)[b] | [60] |
| Indacaterol 150 μg vs tiotropium 18 μg od (blinded), 12 wks | 0.6 (p < 0.001) | −2.1 (p < 0.001) | −0.5 (p < 0.001) | N/A | [94] |
| Indacaterol 150 μg vs tiotropium (blinded), 52 wks[a] | 0.3 (p = 0.02) | 0.2 (NS) | −0.6 (p < 0.001) | 1.24 (p < 0.001) | [95] |

N/A = not applicable (not analyzed or not reported); NS = not significant; TDI = transition dyspnea index; SGRQ = St George's Respiratory Questionnaire.
[a] Study conducted among patients with severe or very severe COPD.
[b] Unpublished data (supplied by study sponsors on request).

on treatment adherence in patients with asthma, mean adherence rates were greater with a once-daily regimen compared with twice daily [115]. In a survey of patients with COPD, those who reported low adherence were more likely to prefer once-daily medication than were those with good adherence; this preference was found to be associated with a high self-perceived need for controller medication [116], indicating the importance of tailoring treatment decisions to the individual patient's needs and preferences. Persistence with inhaled medications for COPD is also directly related to the daily frequency of administration [117].

A fast onset may also be useful in the case of missed doses, a form of non-adherence that is common in COPD [118,101]. Adherence is reported to be lower for medications that do not have an immediate effect on symptoms [102].

## 7. Remaining questions and future research

It is still not firmly established whether long-acting bronchodilators should be started in obstructed patients in the absence of symptoms, and whether it is better to start with a $\beta_2$-adrenergic agonist or an antimuscarinic agent in patients with mild/moderate stable COPD. Thus, in almost all guidelines, no distinction is made as to which class of bronchodilators should be considered first; rather, they only recommend the use of long-acting agents. Similarly, the guidelines do not advise on whether once-daily or twice-daily dosing is preferable, although the weight of evidence supports the better clinical efficacy of the once-daily agents. Moreover, although LABA/LAMA combinations are recommended as an option for patients with increased symptoms and for those at higher risk of exacerbations [1], there is currently no real guidance on when such treatments should be applied in preference to alternative treatments [119]. In any case, it is likely that the lack of indication of bronchodilators class that should be used as first choice is due to the fact that the putative superiority of one class over another documented by some randomized clinical trials was based on only one specific outcome or method of research, the results of which might not be generalizable [119].

Given the many different variables affecting adherence, it is probably an oversimplification to suppose that using a highly efficacious treatment will in itself lead to improved adherence. Indeed, in the TORCH study, the association between increased adherence and improved mortality and reduction in hospital admission was independent of study treatment. The effect of treatment was more pronounced in patients with good adherence than in those with poor adherence, rather than adherence being better in patients receiving the most effective treatment [103].

The relationship between a simple dosing regimen and improved adherence has been reasonably well studied in asthma and COPD [115,116,120], and using a medication dosed once daily should help in addressing the problem of non-adherence. A patient's perception of benefit when restarting a medication or changing to a faster-onset one may be useful to the treating physician in improving the management of a poorly adherent patient. However, further research is warranted to explore the association between a fast onset and adherence, especially in terms of how best to measure fast onset, e.g. patients' perception, subjective experience and clinical effect. Many of these concepts are not easily investigated within the constraints of a randomized, controlled trial, and a more pragmatic approach using observational research will be required.

There are also challenges in terms of how best to define and measure adherence. Research techniques to address adherence with inhaled medication include canister weighing and electronic monitoring of inhaler actuation. Self-reporting is a simple and easy way to assess adherence and is useful in identifying patients'

reasons for non-adherence [121], although the accuracy of this method has been questioned [122]. Numbers of filled prescriptions are used as an indicator of adherence/persistence, but again may not reflect medications taken. Inhalers can now be fitted with electronic monitoring devices that can allow clinicians to track adherence and/or trigger reminders of missed doses direct to the patient. This type of monitoring could help identify barriers to adherence and provide a basis for subsequent discussions with non-adherent patients [123].

In 2008, Bourbeau & Bartlett identified a need to develop effective treatments for COPD with simplified treatment regimens (infrequent dosing, simple delivery), rapid onset of action and durable effect, which would increase the probability of patient adherence [102]. Among the various effective agents available to prescribers today, choosing a once-daily bronchodilator with a fast onset of action (or combination thereof) provides an ideal pharmacodynamic profile that may encourage patient adherence. Use of combination inhalers may improve adherence if it reduces the daily number of medications [101]. Effecting a behavioral change in non-adherent patients requires patient-centered care characterized by concordance (i.e. shared decision-making about therapy by doctors and patients). Effort should be focused on patient education regarding the importance of regular administration and exploring patients' perceptions of their burden of therapy and their goals and expectations from COPD treatment.

## Disclosures

## References

[1] Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. Updated 2014. [accessed 21.07.2014] http://www.goldcopd.org/.

[2] Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012;40: 1545–54.

[3] Thomas M, Decramer M, O'Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 2013;22:101–11.

[4] Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332–8.

[5] Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010;36:65–73.

[6] Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32: 495–506.

[7] Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778–84.

[8] Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek Jr TJ, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47–55.

[9] Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273–9.

[10] Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484–94.

[11] Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477–92.

[12] Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450–504.

[13] Cazzola M, Page CP, Rogliani P, Matera MG. $\beta_2$-agonist therapy in lung disease. Am J Respir Crit Care Med 2013;187:690–6.

[14] Hanania NA, Dickey BF, Bond RA. Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med 2010;16:1–5.

[15] Lötvall J. Pharmacological similarities and differences between beta2-agonists. Respir Med 2001;95(Suppl. B):S7–11.

[16] Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006;317:762–70.

[17] Rosethorne EM, Turner RJ, Fairhurst RA, Charlton SJ. Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn Schmiedeb Arch Pharmacol 2010;382: 255–63.

[18] Slack RJ, Barrett VJ, Morrison VS, Sturton RG, Emmons AJ, Ford AJ, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting $\beta_2$-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther 2013;344:218–30.

[19] Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in pre-clinical models. J Pharmacol Exp Ther 2010;334:53–62.

[20] van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists. Thorax 2001;56:529–35.

[21] Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006;117:18–24.

[22] Chong LK, Peachell PT. Beta-adrenoceptor reserve in human lung: a comparison between airway smooth muscle and mast cells. Eur J Pharmacol 1999;378:115–22.

[23] Broadley KJ. Review of mechanisms involved in the apparent differential desensitization of beta1- and beta2-adrenoceptor-mediated functional responses. J Auton Pharmacol 1999;19:335–45.

[24] Anderson GP. Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. Clin Rev Allergy Immunol 2006;31:119–30.

[25] Green SA, Spasoff AP, Coleman RA, Johnson M, Liggett SB. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the beta2-adrenergic receptor. J Biol Chem 1996;271:24029–35.

[26] Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci 1993;52:2145–60.

[27] Sykes DA, Charlton SJ. Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting $\beta$2-adrenoceptor agonists. Br J Pharmacol 2012;165:2672–83.

[28] Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009;38:533–47.

[29] Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther 2011;337:600–9.

[30] Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 2013;26: 307–17.

[31] Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23:257–67.

[32] Hirshman CA, Lande B, Croxton TL. Role of M2 muscarinic receptors in airway smooth muscle contraction. Life Sci 1999;64:443–8.

[33] Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2: 297–304.

[34] Meurs H, Dekkers BG, Maarsingh H, Halayko AJ, Zaagsma J, Gosens R. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther 2013;26:145–55.

[35] Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther 2012;343:520–8.

[36] Vauquelin G, Charlton SJ. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 2010;161: 488–508.

[37] Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 2009;330: 660–8.

[38] Salmon M, Luttmann MA, Foley JJ, Buckley PT, Schmidt DB, Burman M, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 2013;345:260–70.

[39] Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG. Translational study searching for synergy between glycopyrronium and indacaterol. COPD 2014 Sep 15 [Epub ahead of print].

[40] Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, et al. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur J Pharmacol 2014 Dec 15;745:135–43. http://dx.doi.org/10.1016/j.ejphar.2014.10.025. Epub 2014 Oct 22. PubMed PMID: 25446566.

[41] Kume H, Imbe S, Iwanaga T, Nishiyama O, Sano H, Tohda Y. Involvement of the BK channels/G proteins processes in the synergistic effects between anticholinergic agents and beta2-adrenoceptor agonists in airway smooth muscle. Eur Respir J 2013;42(Suppl. 57):3032 [Abstract].

[42] Cazzola M, Calzetta L, Page CP, Matera MG. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol 2014;10:129–37.

[43] Sechaud R, Renard D, Zhang-Auberson L, Motte Sde L, Drollmann A, Kaiser G. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic

obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther 2012;50: 118–28.

[44] Verkindre C, Fukuchi Y, Flémale A, Takeda A, Overend T, Prasad N, et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010;104:1482–9.

[45] Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Güçlü SZ, Spangenthal S, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010;23:438–44.

[46] Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012 Jul;106(7):970–9. http://dx.doi.org/10.1016/j.rmed.2012.03.012. Epub 2012 Apr 10. PubMed PMID: 22498110.

[47] Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995 Sep;8(9):1506–13. PubMed PMID: 8575576.

[48] EMA/CHMP/169578/2012 European Medicines Agency. Committee for medicinal products for human use (CHMP). CHMP assessment report. Eklira Genuair (aclidinium bromide), vol. 24; May 2012. At:, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002211/WC500132663.pdf [accessed 05.01.2015].

[49] Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014 Nov 18;14:178. http://dx.doi.org/10.1186/1471-2466-14-178. PubMed PMID: 25404569; PubMed Central PMCID: PMC4273456.

[50] Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005;2:111–24.

[51] Borrill ZL, Houghton CM, Tal-Singer R, Vessey SR, Faiferman I, Langley SJ, et al. The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol 2008;65:244–52.

[52] O'Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001;18:914–20.

[53] Santus P, Radovanovic D, Henchi S, Di Marco F, Centanni S, D'Angelo E, et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir Physiol Neurobiol 2014;197:36–45.

[54] Boni E, Corda L, Franchini D, Chiroli P, Damiani GP, Pini L, et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 2002;57:528–32.

[55] Diba C, King GG, Berend N, Salome CM. Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea. Respir Med 2011;105:1345–51.

[56] Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B, et al. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010;5:311–8.

[57] Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65:473–9.

[58] Beier J, Beeh KM, Tröger K, Stenglein S, Bräutigam M, Buhl R, et al. Onset of action of formoterol in patients with moderate to severe, partially reversible airflow obstruction assessed by bodyplethysmography. Pneumologie 2002;56:535–41.

[59] Cazzola M, Paggiaro P, Palange P, Bjermer L, Ausin P, Carlsson LG, et al. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study. Clin Drug Investig 2012;32: 147–55.

[60] Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155–62.

[61] Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther 2013;26:256–64.

[62] Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012;142:119–27.

[63] Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014 Jan 2 [Epub ahead of print].

[64] Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med;107:1538–1546.

[65] Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014;9:629–45.

[66] Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD 2013;10:511–22.

[67] Kerwin E, Hébert J, Gallagher N, Martin C, Overend T, Alagappan VK, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012;40:1106–14.

[68] Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 2014;108:584–92.

[69] Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004;17: 35–9.

[70] Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217–24.

[71] D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011;12:156.

[72] Mahler DA, Decramer M, D'Urzo A, Worth H, White T, Alagappan VK, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014;43:1599–609.

[73] Donohue JF, Hanania NA, Sciarappa KA, Goodwin E, Grogan DR, Baumgartner RA, et al. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis 2008;2:37–48.

[74] Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012;40:830–6.

[75] Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210–23. Erratum in: Lancet Respir Med 2013;1:186.

[76] Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014;2:472–86.

[77] Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014;9:697–714.

[78] Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013;107:1558–67.

[79] O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med 1992;327:1204–8.

[80] Cazzola M, Matera MG. Tremor and β(2)-adrenergic agents: is it a real clinical problem? Pulm Pharmacol Ther 2012;25:4–10.

[81] Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003;21:86–94.

[82] Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264–72.

[83] Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res 2013;14:112.

[84] Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009;3: 1–11.

[85] Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741–50.

[86] Roche N, Small M, Broomfield S, Higgins V, Pollard R. Real world COPD: association of morning symptoms with clinical and patient reported outcomes. COPD 2013;10:679–86.

[87] Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013;188:e13–64.

[88] Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128: 1168–78.

[89] Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012;7:503–13.

[90] O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011;105:1030–6.

[91] Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011;105:719–26.

[92] Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008;102:1511–20.

[93] Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-Van Mölken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093–103.

[94] Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011;38:797–803.

[95] Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013;1:524–33.

[96] Chapman KR, Beeh KM, Beier J, Bateman ED, D'Urzo A, Nutbrown R, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 2014;14:4.

[97] Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199–209.

[98] Mehuys E, Boussery K, Adriaens E, Van Bortel L, De Bolle L, Van Tongelen I, et al. COPD management in primary care: an observational, community pharmacy-based study. Ann Pharmacother 2010;44:257–66.

[99] Neugaard BI, Priest JL, Burch SP, Cantrell CR, Foulis PR. Quality of care for veterans with chronic diseases: performance on quality indicators, medication use and adherence, and health care utilization. Popul Health Manag 2011;14:99–106.

[100] Bender BG. Nonadherence in chronic obstructive pulmonary disease patients: what do we know and what should we do next? Curr Opin Pulm Med 2014;20:132–7.

[101] Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008;3:371–84.

[102] Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63:831–8.

[103] Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009;64:939–43.

[104] van Boven JF, Chavannes NH, van der Molen T, Rutten-van Mölken MP, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med 2014;108:103–13.

[105] Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, et al. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in COPD patients. Curr Med Res Opin 2014;30:1427–36.

[106] Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013;107:1481–90.

[107] Simoni-Wastila L, Wei YJ, Qian J, Zuckerman IH, Stuart B, Shaffer T, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a medicare population. Am J Geriatr Pharmacother 2012;10:201–10.

[108] Viejo JL, Martín Escribano P, Romero S, Rodríguez Suárez JR, Sobradillo V, Valencia A. Compliance with inhalation treatment of patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2000;36:319–25.

[109] van Grunsven PM, van Schayck CP, van Deuveren M, van Herwaarden CL, Akkermans RP, van Weel C. Compliance during long-term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study. J Asthma 2000;37:225–34.

[110] Takemura M, Mitsui K, Ido M, Matsumoto M, Koyama M, Inoue D, et al. Effect of a network system for providing proper inhalation technique by community pharmacists on clinical outcomes in COPD patients. Int J Chron Obstruct Pulmon Dis 2013;8:239–44.

[111] Gallefoss F, Bakke PS. How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication? Am J Respir Crit Care Med 1999;160:2000–5.

[112] Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105:435–41.

[113] Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med 2007;101:1895–902.

[114] Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ 2011;14:486–96.

[115] Price D, Robertson A, Bullen K, Rand C, Home R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010;10. http://dx.doi.org/10.1186/1471-2466-10-1.

[116] Price D, Lee AJ, Sims EJ, Kemp L, Hillyer EV, Chisholm A, et al. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim Care Respir J 2013;22:161–8.

[117] Cramer JA, Bradley-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J 2007;14:25–9.

[118] Laforest L, Denis F, Van Ganse E, Ritleng C, Saussier C, Passante N, et al. Correlates of adherence to respiratory drugs in COPD patients. Prim Care Respir J 2010 Jun;19(2):148–54. http://dx.doi.org/10.4104/pcrj.2010.00004. PubMed PMID: 20094689.

[119] Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med 2014;35:191–201.

[120] Price D, Chisholm A, Hillyer EV, Burden A, von Ziegenweidt J, Svedsater H, et al. Effect of inhaled corticosteroid therapy step-down and dosing regimen on measures of asthma control. J Aller Ther 2013;4:1.

[121] George J, Kong DC, Stewart K. Adherence to disease management programs in patients with COPD. Int J Chron Obstruct Pulmon Dis 2007;2:253–62.

[122] Tommelein E, Mehuys E, Van Tongelen I, Brusselle G, Boussery K. Accuracy of the medication adherence report scale (MARS-5) as a quantitative measure of adherence to inhalation mesdication in patients with COPD. Ann Pharmacother 2014;48:589–95.

[123] Chan AH, Reddel HK, Apter A, Eakin M, Riekert K, Foster JM. Adherence monitoring and e-health: how clinicians and researchers can use technology to promote inhaler adherence for asthma. J Allergy Clin Immunol Pract 2013;1:446–54.